USPTO Examiner NEGIN RUSSELL SCOTT - Art Unit 1672

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17253023MRI STREAK-ARTIFACT SUPPRESSION, SYSTEM AND METHODDecember 2020May 2024Allow4110YesNo
17100062REDUCTION OF BIAS IN GENOMIC COVERAGE MEASUREMENTSNovember 2020May 2023Allow3010NoNo
17073074METHODS AND SYSTEMS FOR GENERATION AND ERROR-CORRECTION OF UNIQUE MOLECULAR INDEX SETS WITH HETEROGENEOUS MOLECULAR LENGTHSOctober 2020April 2023Allow3010NoNo
17039106NUCLEIC ACID AMPLIFICATION AND DETECTION DEVICES, SYSTEMS AND METHODSSeptember 2020October 2023Allow3611YesNo
16978286METHOD AND APPARATUS FOR MONITORING A HUMAN OR ANIMAL SUBJECTSeptember 2020July 2024Abandon4610NoNo
16937464SIGNAL ENCODING AND DECODING IN MULTIPLEXED BIOCHEMICAL ASSAYSJuly 2020August 2023Allow3720YesNo
16936885SIMULATION OF THE DEPLOYMENT OF AN ENDOPROSTHESIS IN REAL TIMEJuly 2020April 2024Allow4510NoNo
16934994SYSTEMS AND METHODS FOR IDENTIFYING STRUCTURAL VARIANTSJuly 2020March 2024Allow4410YesNo
16927533DENSITY-FUNCTIONAL THEORY DETERMINATIONS USING A QUANTUM COMPUTING SYSTEMJuly 2020January 2024Allow4220YesNo
16960830PEELING TYPE LASER TOOTH PREPARING METHOD, APPARATUS AND DEVICE, AND MEDIUMJuly 2020March 2024Allow4410YesNo
16921303DISTRIBUTED DATA ANALYTICSJuly 2020July 2023Allow3610YesNo
16912877METHOD FOR IMPROVING VEGF-RECEPTOR BLOCKING SELECTIVITY OF AN ANTI-VEGF ANTIBODYJune 2020July 2024Abandon4921NoNo
15929565MODELS FOR ANALYZING DATA FROM SEQUENCING-BY-SYNTHESIS OPERATIONSMay 2020January 2023Allow3210NoNo
16866922PERSONALIZED COSMETIC SYSTEMMay 2020January 2023Allow3311YesNo
16866221ENGINEERED MICROPARTICLES FOR MACROMOLECULE DELIVERYMay 2020January 2023Allow3311NoNo
16864744SIGNAL ENCODING AND DECODING IN MULTIPLEXED BIOCHEMICAL ASSAYSMay 2020August 2023Allow3920YesNo
16846346Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditionsApril 2020December 2022Abandon3210NoNo
16831747SCAFFOLD-ORIENTED UNIVERSAL LINE SYSTEMMarch 2020April 2024Allow4911NoNo
16813136NMR Quantification of TMAOMarch 2020June 2023Allow3920YesNo
16801588Quantum Mechanical/X-ray Crystallography Diagnostic for ProteinsFebruary 2020February 2023Allow3510YesNo
16777597METHOD, PROCESSOR DEVICE AND COMPUTER PROGRAM PRODUCT FOR DESIGNING INTERVENTION INTO THE BEHAVIOUR OF A REAL COMPLEX SYSTEMJanuary 2020February 2024Allow4801YesNo
16775233METHODS AND APPARATUS FOR IDENTIFYING DISEASE STATUS USING BIOMARKERSJanuary 2020April 2023Abandon3910NoNo
16740989APPARATUS AND METHOD FOR ESTIMATING ANALYTE CONCENTRATIONJanuary 2020October 2023Allow4520YesNo
16723086QUANTUM COMPUTING THERMODYNAMIC OBSERVABLES OF A CHEMICAL SYSTEMDecember 2019April 2023Allow4030YesNo
16692085Composition Tracking of Mixed Species in Chemical ProcessesNovember 2019June 2023Allow4310YesNo
16680468METHOD AND APPARATUS FOR ANALYTE MEASUREMENTS USING CALIBRATION SETSNovember 2019April 2023Abandon4110NoNo
16673104Methods, Systems and Computer Programs for Assessing CHD Risk Using Adjusted HDL Particle Number MeasurementsNovember 2019November 2023Allow4820YesNo
16663243SYSTEMS AND METHODS FOR ADAPTIVE LOCAL ALIGNMENT FOR GRAPH GENOMESOctober 2019June 2023Allow4320NoNo
16660059PRECISION-PRESERVING QUBIT REDUCTION BASED ON SPATIAL SYMMETRIES IN FERMIONIC SYSTEMSOctober 2019October 2023Allow4820YesNo
16605298METHODS FOR PREPARING OPTIMAL COMBINATION OF OLIGONUCLEOTIDESOctober 2019February 2024Allow5211NoNo
16601350SYSTEMS AND METHODS FOR SIMULATION-BASED RADIATION ESTIMATION AND PROTECTION FOR MEDICAL PROCEDURESOctober 2019January 2023Abandon3910NoNo
16595758RATIONAL DRUG DESIGN WITH COMPUTATIONAL FREE ENERGY DIFFERENCE CALCULATION USING A MODIFIED BOND STRETCH POTENTIALOctober 2019September 2022Allow3510NoNo
16549684METHODS FOR NUCLEIC ACID SIZE DETECTION OF REPEAT SEQUENCESAugust 2019October 2023Allow5020NoNo
16529760METHOD AND SYSTEM FOR ANATOMICAL TREE STRUCTURE ANALYSISAugust 2019July 2022Allow3610NoNo
16525822SYSTEMS AND METHODS FOR ANALYZING CIRCULATING TUMOR DNAJuly 2019August 2022Allow3710NoNo
16506388CHD Risk Stratification Evaluations for Subjects With High Levels of Large HDL-PJuly 2019March 2023Allow4420YesNo
16506287METHODS, SYSTEMS AND PROCESSES OF IDENTIFYING GENETIC VARIATION IN HIGHLY SIMILAR GENESJuly 2019November 2022Allow4111NoNo
16460269Multi-Parameter Diabetes Risk EvaluationsJuly 2019March 2023Allow4420YesNo
16445712SYSTEM AND METHOD FOR HARMONIC MODULATION OF STANDING WAVEFIELDS FOR SPATIAL FOCUSING, MANIPULATION, AND PATTERNINGJune 2019March 2023Allow4510YesNo
16441690ENCODING DATA FROM GENETIC TRAITS RELEVANT TO ILLNESS DIAGNOSIS AND HERITAGEJune 2019February 2023Allow4420YesNo
16470140CLASSIFICATION ANALYSIS METHOD, CLASSIFICATION ANALYSIS DEVICE, AND STORAGE MEDIUM FOR CLASSIFICATION ANALYSISJune 2019February 2023Abandon4420NoNo
16435406SCAR-LESS MULTI-PART DNA ASSEMBLY DESIGN AUTOMATIONJune 2019April 2023Allow4610NoNo
16434677SYSTEMS AND METHODS FOR IDENTIFYING SEQUENCE VARIATION ASSOCIATED WITH GENETIC DISEASESJune 2019April 2023Allow4620YesNo
16405050IDENTIFICATION USING SPECTROSCOPYMay 2019February 2023Allow4530YesNo
16397281SYSTEM AND METHOD FOR MOLECULAR DESIGN ON A QUANTUM COMPUTERApril 2019March 2023Allow4720NoNo
16380489INTENSITY NORMALIZATION IN IMAGING MASS SPECTROMETRYApril 2019June 2023Allow5030YesNo
16377680BIOLOGICAL INFORMATION PROCESSING METHOD AND DEVICE, RECORDING MEDIUM AND PROGRAMApril 2019March 2023Allow4741YesNo
16089593SCREENING METHOD FOR CANDIDATE SUBSTANCES FOR ACTIVE COMPONENT TO PREVENT OR TREAT AT LEAST ONE DISEASE SELECTED FROM THE GROUP CONSISTING OF RENAL HYPOFUNCTION, CHRONIC KIDNEY DISEASE AND KIDNEY FAILUREMarch 2019October 2023Allow6011NoNo
16355886METHOD FOR MEASURING A BIOLOGICAL VALUE OF A LIVERMarch 2019November 2022Abandon4401NoNo
16284470INTERACTIVE-AWARE CLUSTERING OF STABLE STATESFebruary 2019August 2022Allow4230YesNo
16269092METHOD AND APPARATUS FOR GENERATING CHEMICAL STRUCTURE USING NEURAL NETWORKFebruary 2019January 2023Allow4811YesNo
16258299MACHINE LEARNING ENABLED PULSE AND BASE CALLING FOR SEQUENCING DEVICESJanuary 2019August 2022Allow4310NoNo
16249803Discovering Population Structure From Patterns of Identity-By-DescentJanuary 2019August 2022Allow4310YesNo
16245306ANALYSIS OF MEASUREMENTS OF A POLYMERJanuary 2019December 2023Allow5950YesNo
16226575SYSTEMS AND METHODS FOR DE NOVO PEPTIDE SEQUENCING FROM DATA-INDEPENDENT ACQUISITION USING DEEP LEARNINGDecember 2018February 2023Allow5011NoNo
16191069METHOD FOR ANALYZING SULFIDE-BASED SOLID ELECTROLYTE USING COMPUTER SIMULATION AND PROGRAM FOR ANALYZING SULFIDE-BASED SOLID ELECTROLYTE USING COMPUTER SIMULATIONNovember 2018November 2022Allow4811NoNo
16179280METHODS AND SYSTEMS FOR PRODUCING AN EXPANDED TRAINING SET FOR MACHINE LEARNING USING BIOLOGICAL SEQUENCESNovember 2018May 2023Allow5420NoNo
16097897METHODS FOR IDENTIFYING TREATMENT TARGETS BASED ON MULTIOMICS DATAOctober 2018January 2023Allow5011NoNo
16172289METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATIONOctober 2018September 2022Allow4711NoNo
16081102IN SILICO PROCESS FOR SELECTING PROTEIN FORMULATION EXCIPIENTSAugust 2018July 2022Allow4720NoNo
16053679GRAPH NEURAL NETWORKS FOR REPRESENTING MICROORGANISMSAugust 2018October 2022Abandon5010NoNo
16037949METHODS AND SYSTEMS FOR DE NOVO PEPTIDE SEQUENCING USING DEEP LEARNINGJuly 2018November 2022Allow5231YesNo
16035470SYSTEMS AND METHODS FOR MULTIPLEX PCR PRIMER SELECTIONJuly 2018July 2022Allow4811NoNo
15780673METHODS AND SYSTEMS FOR DETERMINATION OF THE NUMBER OF CONTRIBUTORS TO A DNA MIXTUREJune 2018April 2024Allow6020NoNo
15984129COMPUTATIONAL METHOD FOR CLASSIFYING AND PREDICTING LIGAND DOCKING CONFORMATIONSMay 2018July 2022Allow5011NoNo
15957883USES OF SYSTEMS WITH DEGREES OF FREEDOM POISED BETWEEN FULLY QUANTUM AND FULLY CLASSICAL STATESApril 2018March 2023Abandon5921NoNo
15947255MEASUREMENT METHOD, MEASURING APPARATUS, PROGRAM, AND METHOD FOR OBTAINING AND DISPLAYING QUALITATIVE DETERMINATION RESULTApril 2018July 2022Allow5120YesNo
15918369COMPENSATION FOR SPECTRAL CROSSTALK IN MULTIPLEX NUCLEIC ACID AMPLIFICATIONMarch 2018October 2022Allow5530YesNo
15899866Predictive Test for Prognosis of Myelodysplastic Syndrome Patients Using Mass Spectrometry of Blood-Based SampleFebruary 2018October 2022Allow5640YesNo
15579363A Method Of Assessing Protein Modification Status And Identifying Biomarkers Linked To Cell Signaling PathwaysDecember 2017November 2023Abandon6041NoNo
15440269Systems and Methods for Collecting and Transmitting Assay ResultsFebruary 2017July 2024Abandon6051NoYes
15433396COMPOSITIONS AND METHODS FOR PROTEIN PRODUCTIONFebruary 2017August 2022Allow6051NoNo
15040729SYSTEMS AND METHODS FOR IMAGING CHANGES IN TISSUEFebruary 2016October 2022Abandon6061YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NEGIN, RUSSELL SCOTT.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner NEGIN, RUSSELL SCOTT - Prosecution Strategy Guide

Executive Summary

Examiner NEGIN, RUSSELL SCOTT works in Art Unit 1672 and has examined 73 patent applications in our dataset. With an allowance rate of 82.2%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner NEGIN, RUSSELL SCOTT's allowance rate of 82.2% places them in the 56% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by NEGIN, RUSSELL SCOTT receive 1.78 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NEGIN, RUSSELL SCOTT is 45 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +27.8% benefit to allowance rate for applications examined by NEGIN, RUSSELL SCOTT. This interview benefit is in the 74% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.3% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 76.2% of cases where such amendments are filed. This entry rate is in the 95% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 111.1% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.